

CERTIFICATE

Survey of 20 May 2022

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 25 - Apixaban (504):

Validity 12 months:

Apixaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr. Martin Spacek, PhD.

Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratoře ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 14 July 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 20 May 2022

You have participated in the External Quality Assessment with the following analysis

Haemostasis 25 - Apixaban (504):

Apixaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr. Martin Spacek, PhD.


Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratorie ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 14 July 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)